MiMedx Group, Inc. (MDXG)
- Previous Close
6.16 - Open
6.11 - Bid 6.27 x 200
- Ask 6.32 x 100
- Day's Range
6.10 - 6.30 - 52 Week Range
3.49 - 9.27 - Volume
691,153 - Avg. Volume
788,666 - Market Cap (intraday)
924.366M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
14.63 - EPS (TTM)
0.43 - Earnings Date Apr 30, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.50
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
www.mimedx.comRecent News: MDXG
Performance Overview: MDXG
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDXG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDXG
Valuation Measures
Market Cap
905.26M
Enterprise Value
871.36M
Trailing P/E
14.33
Forward P/E
19.27
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.80
Price/Book (mrq)
6.34
Enterprise Value/Revenue
2.71
Enterprise Value/EBITDA
21.51
Financial Highlights
Profitability and Income Statement
Profit Margin
18.11%
Return on Assets (ttm)
11.30%
Return on Equity (ttm)
62.09%
Revenue (ttm)
321.48M
Net Income Avi to Common (ttm)
55.8M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
82M
Total Debt/Equity (mrq)
35.42%
Levered Free Cash Flow (ttm)
26.15M
Research Analysis: MDXG
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell